ATOS - Atossa Genetics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Atossa Genetics Inc.

107 Spring Street
Seattle, WA 98104
United States
206-325-6068
http://www.atossagenetics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Steven C. QuayChairman, CEO & Pres800.33kN/A1951
Mr. Kyle Guse CPA, Esq., CPACFO, Gen. Counsel & Sec.576.33kN/A1964
Ms. Janet Rose ReaSr. VP of Regulatory, Quality & Clinical AffairsN/AN/AN/A
Dr. Jack CuzickMember of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atossa Genetics Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Its lead program is the development of Endoxifen, conducting two Phase II studies, which is an active metabolite of tamoxifen to treat and prevent breast cancer. The company is also developing intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. Its medical devices also include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator, which collect specimens of nipple aspirate fluid for cytological testing. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Corporate Governance

Atossa Genetics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.